Extrait

This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.

Critère d'inclusion

• Gastrointestinal stromal tumor

Liens

• nct
• ictrp